Advanced search
Start date

Analysis of cytotoxicity of 5-fluorouracil associated with cisplatin and taurine in cervical cancer cells

Grant number: 17/23734-0
Support Opportunities:Scholarships in Brazil - Scientific Initiation
Effective date (Start): February 01, 2018
Effective date (End): July 31, 2018
Field of knowledge:Health Sciences - Pharmacy - Toxicological Analysis
Principal Investigator:Christiane Pienna Soares
Grantee:Isabela Leone Gaspardo
Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil


The cervical cancer was responsable for 265 mil deaths and the appearance of 527 thousands new cases of cervical cancer in the world in 2012. In Brazil, 16,340 new cases of cervical cancer were estimated in 2016 and about 70% of these neoplasms were caused by HPV 16 and 18 viruses. Although several antitumor therapies are on the market, there are patients who do not respond to treatment, leading to the use of high doses of antineoplastic agents, consequently, there is an increase in side effects and a decrease in patients' quality of life. Thus, the combination of the antineoplastic agents with other substances may be an alternative for improving efficacy, reducing the dose and side effects of the treatment, as well as minimizing drug resistance. Thus, this study aims to evaluate the cytotoxicity of 5-fluorouracil associated with cisplatin and taurine by the in vitro assay of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-2H- tetrazolium bromide) in SiHa (squamous cell carcinoma grade II), C-33A (cervical carcinoma) and HaCaT (human keratinocytes) cell lines. In addition, the study will examine whether there is a synergistic interaction of combined 5-fluorouracil with cisplatin as well as 5-fluorouracil associated with taurine by the Chou-Talalay method. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list by writing to: